Cantargia AB (CHIX:CANTAS) EBIT per Share: kr0.72 (TTM As of Mar. 2026)


CHIX:CANTAS Cantargia AB CHIX:CANTAS
37 GF Score
Price kr4.17
! 2 Warning Signs
View Full Analysis

What is Cantargia AB EBIT per Share?

Cantargia AB CHIX:CANTAS 37 EBIT per Share is kr0.72 as of Mar. 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 1,174 Biotechnology companies, Cantargia AB ranks worse than 85178.79% on this metric.

Cantargia AB's EBIT per Share for the three months ended in Mar. 2026 was kr-0.11. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.72.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cantargia AB's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Cantargia AB was 37.00% per year. The lowest was -69.10% per year. And the median was -31.90% per year.

CHIX:CANTAs's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Cantargia AB's EBIT for the three months ended in Mar. 2026 was kr-27.1 Mil.

Cantargia AB  (CHIX:CANTAs) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cantargia AB EBIT per Share Related Terms

Cantargia AB EBIT per Share Historical Data

* Premium members only.

The historical data trend for Cantargia AB's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantargia AB EBIT per Share Chart

Cantargia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.66 -2.90 -1.65 -0.88 0.60

Cantargia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.15 1.08 -0.10 -0.11
CHIX:CANTAS
37GF Score
Cantargia AB CHIX:CANTAS
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cantargia AB EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cantargia AB's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=151.099/253.795
=0.60

Cantargia AB's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-27.125/248.612
=-0.11

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of kr0.72 mean?
Cantargia AB (CHIX:CANTAS) has a EBIT per Share of kr0.72 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cantargia AB and its competitors. According to the industry distribution chart, Cantargia AB ranks #999999 out of 1174 companies in the Biotechnology industry.
Is Cantargia AB's EBIT per Share too high?
Cantargia AB's current EBIT per Share is kr0.72. Based on the distribution chart, Cantargia AB ranks #999999 out of 1174 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #999999 out of 1174 companies for EBIT per Share. This places Cantargia AB in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Cantargia AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantargia AB's current EBIT per Share is kr0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current EBIT per Share of kr0.72. The current EBIT per Share is kr0.72. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current EBIT per Share is kr0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantargia AB Business Description

Other Exchanges CANTA:Sweden7V3:Germany
Address Scheelevagen 27, Lund, SWE, 223 63
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score

Get the complete analysis for CHIX:CANTAS

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.17
Price